Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study.
Adult
Aged
Angiopoietin-Like Protein 6
Angiopoietin-like Proteins
/ blood
Biomarkers
/ blood
Blood Glucose
/ analysis
Enzyme-Linked Immunosorbent Assay
Humans
Incidence
Lipoproteins, HDL
/ blood
Male
Metabolic Syndrome
/ blood
Middle Aged
Prevalence
Prognosis
Prospective Studies
ROC Curve
Republic of Korea
/ epidemiology
Rural Population
Triglycerides
/ blood
ANGPTL6 protein, human
Biomarkers
Metabolic syndrome
Prospective studies
ROC curve
Journal
Diabetes & metabolism journal
ISSN: 2233-6079
Titre abrégé: Diabetes Metab J
Pays: Korea (South)
ID NLM: 101556588
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
16
05
2018
accepted:
21
12
2018
pubmed:
11
4
2019
medline:
11
4
2019
entrez:
11
4
2019
Statut:
ppublish
Résumé
Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome. In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations. During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.
Sections du résumé
BACKGROUND
Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome.
METHODS
In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations.
RESULTS
During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL,
CONCLUSION
Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.
Identifiants
pubmed: 30968619
pii: 43.e25
doi: 10.4093/dmj.2018.0080
pmc: PMC6712233
doi:
Substances chimiques
ANGPTL6 protein, human
0
Angiopoietin-Like Protein 6
0
Angiopoietin-like Proteins
0
Biomarkers
0
Blood Glucose
0
Lipoproteins, HDL
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
521-529Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Korean Diabetes Association.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Exp Mol Med. 2017 Feb 3;49(2):e291
pubmed: 28154371
Metabolism. 2009 Apr;58(4):547-51
pubmed: 19303977
Trends Mol Med. 2005 Oct;11(10):473-9
pubmed: 16154386
Yonsei Med J. 2018 Mar;59(2):287-293
pubmed: 29436198
J Diabetes Investig. 2015 Sep;6(5):508-15
pubmed: 26417407
Blood. 2004 May 15;103(10):3760-5
pubmed: 14764539
J Investig Med. 2012 Jun;60(5):813-7
pubmed: 22406517
Diabetes Metab J. 2013 Dec;37(6):433-49
pubmed: 24404515
Nat Med. 2005 Apr;11(4):400-8
pubmed: 15778720
Dose Response. 2012;10(2):177-89
pubmed: 22740780
Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36
pubmed: 18174459
Circ J. 2006 Jul;70(7):820-6
pubmed: 16799232
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Diabetes Care. 2013 Jun;36(6):1547-53
pubmed: 23275369
Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):72-7
pubmed: 19747805
Am J Hypertens. 2009 Mar;22(3):314-8
pubmed: 19057519
Circulation. 2004 Jul 27;110(4):380-5
pubmed: 15262834
Metabolism. 2011 Apr;60(4):564-8
pubmed: 20673930
Horm Metab Res. 2014 Sep;46(10):685-90
pubmed: 25011017
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
Diabetes Metab Res Rev. 2002 Sep-Oct;18(5):345-56
pubmed: 12397577
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
pubmed: 17258085
Diabetes Care. 2011 Jun;34(6):1323-8
pubmed: 21505206
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Pharmacol Exp Ther. 2007 Dec;323(3):787-93
pubmed: 17804676
Biochem Biophys Res Commun. 2018 Jul 20;502(3):397-402
pubmed: 29852166
J Endocrinol. 2017 Apr;233(1):105-118
pubmed: 28184000
PLoS One. 2011;6(5):e19835
pubmed: 21625549
J Biol Chem. 2005 Jan 7;280(1):847-51
pubmed: 15509553
Diabetes Res Clin Pract. 2007 Jan;75(1):72-80
pubmed: 16735075
J Hypertens. 2007 Aug;25(8):1671-7
pubmed: 17620965
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9494-9
pubmed: 12871997
Nat Med. 2013 Jan;19(1):83-92
pubmed: 23202295
Trends Endocrinol Metab. 2009 May;20(4):194-201
pubmed: 19349192
Metabolism. 2016 Aug;65(8):1049-61
pubmed: 26997538
Obes Rev. 2002 Aug;3(3):141-6
pubmed: 12164465